The Tri-Institutional Therapeutics Discovery Institute, a partnership with Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, works to more effectively develop therapeutics that arise from discoveries made in basic science labs. With a focus on early stage drug discovery, the institute provides expertise in medicinal chemistry and compound screening and conducts “proof of concept” studies needed to demonstrate that drug candidates can successfully alter the course of a disease. The institute also works to provide high-quality opportunities for training students and postdoctoral fellows, to deepen faculty involvement in drug discovery and to support translational research by leveraging the expertise of all three academic institutions and industry partners. An independent nonprofit corporation with its own board of directors and scientific advisory committee, the institute facilitates more efficient sharing of core facilities between the three partner institutions and works to form industry partnerships with pharmaceutical and biotech companies to further advance drug research. It also seeks to create intellectual property that can be further developed by an open field of industry collaborators.
For more information visit the Tri-Institutional Therapeutics Discovery Institute